Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is

ALISO VIEJO, Calif. - July 17, 2020 - PRLog -- The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.

§  A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.

§  Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  An analysis of the various expansion initiatives undertaken by the players in this domain.

§  An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.

§  A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.

§  A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry's evolution.

§  A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of Product

§  HPAPIs

§  Highly Potent Finished Dosage Forms

§  Company Size

§  Small-sized

§  Mid-sized

§  Large / Very Large

§  Scale of Operation

§  Preclinical / Clinical

§  Commercial

The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:

§  Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)

§  Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)

§  Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Other Recent Offerings

1.      Antibody Contract Manufacturing Market, 2020 – 2030

2.      Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030

3.      Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com